{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T09:38:17Z","timestamp":1775900297422,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"National Science and Technology Major Project of China","award":["2012ZX09301002-001-007"],"award-info":[{"award-number":["2012ZX09301002-001-007"]}]},{"name":"National Science and Technology Major Project of China","award":["2012ZX09301002-006"],"award-info":[{"award-number":["2012ZX09301002-006"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81202545"],"award-info":[{"award-number":["81202545"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81302847"],"award-info":[{"award-number":["81302847"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81473096"],"award-info":[{"award-number":["81473096"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.dmpk.2016.07.002","type":"journal-article","created":{"date-parts":[[2016,7,16]],"date-time":"2016-07-16T09:14:48Z","timestamp":1468660488000},"page":"53-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Identification of cytochrome P450 isoforms involved in the metabolism of Syl930, a selective S1PR1 agonist acting as a potential therapeutic agent for autoimmune encephalitis"],"prefix":"10.1016","volume":"32","author":[{"given":"Jiaqi","family":"Mi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manman","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baolian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinping","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmpk.2016.07.002_bib1","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S1474-4422(10)70064-8","article-title":"The changing demographic pattern of multiple sclerosis epidemiology","volume":"9","author":"Koch-Henriksen","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.dmpk.2016.07.002_bib2","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJM200009283431307","article-title":"Multiple sclerosis","volume":"343","author":"Noseworthy","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dmpk.2016.07.002_bib3","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1056\/NEJM199801293380502","article-title":"Axonal transection in the lesions of multiple sclerosis","volume":"338","author":"Trapp","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dmpk.2016.07.002_bib4","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3389\/fimmu.2015.00642","article-title":"B\u00a0cells are multifunctional players in multiple sclerosis pathogenesis: insights from therapeutic interventions","volume":"6","author":"Claes","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.dmpk.2016.07.002_bib5","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)","volume":"39","author":"Jacobs","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/j.dmpk.2016.07.002_bib6","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","article-title":"Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial","volume":"45","author":"Johnson","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.dmpk.2016.07.002_bib7","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1212\/WNL.0b013e3181e0f7e6","article-title":"Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS","volume":"74","author":"Kingwell","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.dmpk.2016.07.002_bib8","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s12325-011-0004-6","article-title":"Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis","volume":"28","author":"Yeh","year":"2011","journal-title":"Adv Ther"},{"key":"10.1016\/j.dmpk.2016.07.002_bib9","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd3248","article-title":"Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis","volume":"9","author":"Brinkmann","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.dmpk.2016.07.002_bib10","doi-asserted-by":"crossref","first-page":"21453","DOI":"10.1074\/jbc.C200176200","article-title":"The immune modulator FTY720 targets sphingosine 1-phosphate receptors","volume":"277","author":"Brinkmann","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.dmpk.2016.07.002_bib11","doi-asserted-by":"crossref","first-page":"9082","DOI":"10.1074\/jbc.M610318200","article-title":"Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor","volume":"282","author":"Oo","year":"2007","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.dmpk.2016.07.002_bib12","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.msard.2014.03.002","article-title":"Fingolimod in relapsing multiple sclerosis: an integrated analysis of safety findings","volume":"3","author":"Kappos","year":"2014","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.dmpk.2016.07.002_bib13","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1517\/14656566.2010.481671","article-title":"Oral fingolimod for relapsing-remitting multiple sclerosis","volume":"11","author":"Doggrell","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.dmpk.2016.07.002_bib14","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1124\/dmd.110.035378","article-title":"CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis","volume":"39","author":"Jin","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2016.07.002_bib15","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1124\/dmd.105.009001","article-title":"Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses","volume":"34","author":"Meno-Tetang","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2016.07.002_bib16","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1124\/jpet.301.2.519","article-title":"Pharmacokinetics and cell trafficking dynamics of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride (FTY720) in cynomolgus monkeys after single oral and intravenous doses","volume":"301","author":"Li","year":"2002","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.dmpk.2016.07.002_bib17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/bdd.535","article-title":"Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects","volume":"28","author":"Kovarik","year":"2007","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.dmpk.2016.07.002_bib18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bcp.2014.04.010","article-title":"Development of a selective S1P1 receptor agonist, Syl930, as a potential therapeutic agent for autoimmune encephalitis","volume":"90","author":"Jin","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.dmpk.2016.07.002_bib19","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/j.bmc.2016.03.059","article-title":"Synthesis, identification, and biological activity of metabolites of two novel selective S1P1 agonists","volume":"24","author":"Xiao","year":"2016","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.dmpk.2016.07.002_bib20","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jchromb.2007.01.006","article-title":"Validated method for rapid inhibition screening of six cytochrome P450 enzymes by liquid chromatography-tandem mass spectrometry","volume":"852","author":"Li","year":"2007","journal-title":"J\u00a0Chromatogr B Anal Technol Biomed Life Sci"},{"key":"10.1016\/j.dmpk.2016.07.002_bib21","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/nrc2015","article-title":"The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis","volume":"6","author":"Nebert","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.dmpk.2016.07.002_bib22","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1124\/dmd.104.000794","article-title":"Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi\/AUC) ratios","volume":"32","author":"Williams","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2016.07.002_bib23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1021\/tx700079z","article-title":"Cytochrome p450 and chemical toxicology","volume":"21","author":"Guengerich","year":"2008","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.dmpk.2016.07.002_bib24","doi-asserted-by":"crossref","first-page":"13682","DOI":"10.1073\/pnas.0603236103","article-title":"Structural basis for ligand promiscuity in cytochrome P450 3A4","volume":"103","author":"Ekroos","year":"2006","journal-title":"Proc Natl Acad Sci U. S. A"},{"key":"10.1016\/j.dmpk.2016.07.002_bib25","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1172\/JCI113156","article-title":"Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man","volume":"80","author":"Watkins","year":"1987","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.dmpk.2016.07.002_bib26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.pharmthera.2009.05.011","article-title":"Cooperative properties of cytochromes P450","volume":"124","author":"Denisov","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2016.07.002_bib27","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1021\/bi0481390","article-title":"The thermodynamic landscape of testosterone binding to cytochrome P450 3A4: ligand binding and spin state equilibria","volume":"44","author":"Roberts","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.dmpk.2016.07.002_bib28","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00124743-199906000-00007","article-title":"Drug interactions affecting the efficacy of corticosteroid therapy a brief review with an illustrative case","volume":"5","author":"Feldweg","year":"1999","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.dmpk.2016.07.002_bib29","doi-asserted-by":"crossref","first-page":"9376","DOI":"10.1016\/S0021-9258(18)98360-2","article-title":"A\u00a0novel form of cytochrome P-450 family 4 in human polymorphonuclear leukocytes. cDNA cloning and expression of leukotriene B4 omega-hydroxylase","volume":"268","author":"Kikuta","year":"1993","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.dmpk.2016.07.002_bib30","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.bcp.2008.03.004","article-title":"Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases","volume":"75","author":"Hardwick","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.dmpk.2016.07.002_bib31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/abbi.1998.0880","article-title":"Role of human CYP4F2 in hepatic catabolism of the proinflammatory agent leukotriene B4","volume":"359","author":"Jin","year":"1998","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.dmpk.2016.07.002_bib32","doi-asserted-by":"crossref","first-page":"13180","DOI":"10.1074\/jbc.M513481200","article-title":"Omega-oxidation of very long-chain fatty acids in human liver microsomes. Implications for X-linked adrenoleukodystrophy","volume":"281","author":"Sanders","year":"2006","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.dmpk.2016.07.002_bib33","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1124\/dmd.30.9.1022","article-title":"Sexual dimorphism and tissue specificity in the expression of CYP4F forms in Sprague Dawley rats","volume":"30","author":"Kalsotra","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2016.07.002_bib34","doi-asserted-by":"crossref","first-page":"12932","DOI":"10.1074\/jbc.M113.452953","article-title":"Human cytochrome P450 1A1 structure and utility in understanding drug and xenobiotic metabolism","volume":"288","author":"Walsh","year":"2013","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.dmpk.2016.07.002_bib35","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1074\/jbc.271.7.3460","article-title":"Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart","volume":"271","author":"Wu","year":"1996","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.dmpk.2016.07.002_bib36","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1124\/mol.51.6.931","article-title":"CYP2J subfamily cytochrome P450s in the gastrointestinal tract: expression, localization, and potential functional significance","volume":"51","author":"Zeldin","year":"1997","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.dmpk.2016.07.002_bib37","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0026-895X(25)09539-2","article-title":"CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance","volume":"50","author":"Zeldin","year":"1996","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.dmpk.2016.07.002_bib38","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1164\/ajrccm\/143.1.188","article-title":"Arachidonic acid metabolism. Implications of biological chemistry for lung function and disease","volume":"143","author":"Holtzman","year":"1991","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.dmpk.2016.07.002_bib39","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/17425255.2.6.875","article-title":"Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction","volume":"2","author":"Martignoni","year":"2006","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.dmpk.2016.07.002_bib40","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1681\/ASN.V1341073","article-title":"First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients","volume":"13","author":"Budde","year":"2002","journal-title":"J\u00a0Am Soc Nephrol JASN"},{"key":"10.1016\/j.dmpk.2016.07.002_bib41","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2133\/dmpk.DMPK-12-RG-134","article-title":"Mechanism-based inhibition profiles of erythromycin and clarithromycin with cytochrome P450 3A4 genetic variants","volume":"28","author":"Akiyoshi","year":"2013","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.dmpk.2016.07.002_bib42","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3109\/03602532.2010.549492","article-title":"Macaque cytochromes P450: nomenclature, transcript, gene, genomic structure, and function","volume":"43","author":"Uno","year":"2011","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.dmpk.2016.07.002_bib43","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0090-9556(25)06821-7","article-title":"Comparisons of phase I and phase II in\u00a0vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey","volume":"23","author":"Sharer","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2016.07.002_bib44","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s002040050403","article-title":"Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans","volume":"71","author":"Shimada","year":"1997","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.dmpk.2016.07.002_bib45","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0009-2797(97)00068-9","article-title":"Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species","volume":"106","author":"Guengerich","year":"1997","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.dmpk.2016.07.002_bib46","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3109\/03602539109029764","article-title":"Species differences in metabolism and pharmacokinetics: are we close to an understanding?","volume":"23","author":"Smith","year":"1991","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.dmpk.2016.07.002_bib47","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1006\/abbi.1993.1439","article-title":"Purification and characterization of two forms of hepatic microsomal cytochrome P450 from untreated cynomolgus monkeys","volume":"305","author":"Ohmori","year":"1993","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.dmpk.2016.07.002_bib48","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0167-4781(92)90113-E","article-title":"Molecular cloning of monkey liver cytochrome P-450 cDNAs: similarity of the primary sequences to human cytochromes P-450","volume":"1171","author":"Komori","year":"1992","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.dmpk.2016.07.002_bib49","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0090-9556(24)15229-4","article-title":"Characterization of human small intestinal cytochromes P-450","volume":"27","author":"Zhang","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2016.07.002_bib50","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1039\/c3md00079f","article-title":"Design, synthesis and docking-based 3D-QSAR study of novel 2-substituted 2-aminopropane-1,3-diols as potent and selective agonists of sphingosine-1-phosphate 1 (S1P1) receptor","volume":"4","author":"Tian","year":"2013","journal-title":"Med Chem Comm"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436716300325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436716300325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:54:08Z","timestamp":1761162848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436716300325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S1347436716300325"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2016.07.002","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of cytochrome P450 isoforms involved in the metabolism of Syl930, a selective S1PR1 agonist acting as a potential therapeutic agent for autoimmune encephalitis","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2016.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}